Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study - Top-Institutions - MDSpire

Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study

  • By

  • Huiliang Zhang

  • Qingwen Huang

  • Jitao Du

  • Xiangbin Wan

  • July 3, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Henan Cancer Hospital
    Henan Cancer Hospital

    Zhengzhou, Henan

    Key Differentiators

    • Oncology

  • #2

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #3

    Roswell Park Comprehensive Cancer Center
    Roswell Park Comprehensive Cancer Center

    Buffalo, New York

    Key Differentiators

    • Oncology

Original Source(s)

Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study

  • by Huiliang Zhang, Qingwen Huang, Jitao Du, Xiangbin Wan

  • July 3, 2026

Related Content

A review on in-silico analysis of immune cell trafficking and interactions with the tumour microenvironment

Initial experience with the Carina™ platform for gasless transaxillary robotic thyroidectomy in papillary thyroid carcinoma: an early feasibility report

Inducing tumor-intrinsic innate immune response to break cancer immunotherapy resistance